Cellectar Biosciences receives patent protection for cancer drug
Insight Weekly: Loan delinquencies up; US money supply falls; coal employment grows
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Cellectar Biosciences Inc. received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as associated cancer stem cells.
The patent protection will last through the end of 2035.
